Novast

Novast, a pharmaceutical startup founded in 2005, focuses on bringing advanced generic drugs to the US market through strategic collaborations. With a slogan emphasizing their state-of-the-art facilities and pioneering team, Novast specializes in the research, development, and production of value-added generic drugs with release control and various dosage forms. This is targeted at the US pharmaceutical market through collaboration with leading channels. Notably, Novast is the first pharmaceutical company in China to sell products in the US, achieved through partnerships with US sales channels and original development enterprises. The company operates with cGMP manufacturing facilities covering 18,000 square meters. Novast’s management team possesses extensive experience, having applied for over 100 generic drug patents in the US, and significant experience in the US pharmaceutical industry. Moreover, Novast independently develops multiple technologies for drug delivery and varied dosage types. In January 2021, Novast secured a CNY400.00M venture round investment from HighLight Capital and Shiyu Capital, further consolidating its position for growth and expansion in the industry. With a focus on cutting-edge pharmaceutical development and strategic market collaborations, Novast presents a dynamic opportunity for investment and potential market disruption.